Search Close Search

Lead investigators:
yellow line

Apurv Soni, MD, PhD, David McManus, MD, ScM, John Broach, MD

The status quo:
Yellow Line

Rapid antigen tests’ performance is questioned with different variants and concerns about delay in diagnosis or antigen rebound are raised. Additionally, currently, we primarily rely on swab-based testing for the detection of SARS-CoV-2 infection. ​

What we study:
Yellow Line

STOP COVID-19 study aims to understand how antigen tests perform in comparison to PCR tests for the detection of the SARS-CoV-2 virus after the onset of symptoms. Further, we are exploring the utility of symptomology, wearable sensor data, and other multimodal inputs for the detection of the SARS-CoV-2 virus after the onset of symptoms.  

How we innovate:
Yellow Line

We leverage a siteless design to allow anyone, anywhere, at any time to contribute to this science as long as they have access to a smartphone and reside in USA. This study features the following innovations:

Bring their own device. 

Participants’ own smart devices can be paired with MyDataHelps, a mobile application platform developed by CareEvolution, LLC.

Record symptoms using a participant-friendly diary.

Participants can log symptoms in the MyDataHelps app and access statistics and trends regarding their symptoms and treatments using a tool called Symptom Shark.  

Perform home-based collections for PCR results.

We obtain molecular confirmation of viruses and understand their variant type using home-based PCR collection kits from Quest Diagnostics.

Join this study

The study is now enrolling. Click the button below to find out more.

Join the study

Page Menu

STOP COVID-19: Understanding Rapid Antigen Tests’ Performance during Peri-Acute SARS-CoV-2 Infection Period